Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

Inclusion Criteria: * Subjects with locally advanced or metastatic solid tumor confirmed by histopathology; * Having at least one evaluable or measurable lesion according to the solid tumor response Evaluation Criteria (RECIST 1.1); * For patients with relapsed/refractory neuroblastoma with original diagnosis based on tumor histopathology, Karnofsky or Lansky performance status of ≥ 50%; * ECOG Performance Status from 0 or 3; * The expected survival time is more than 12 weeks; * 2 to 65+ old, gender is not limited; * The subjects gave informed consent to the study before participating in, and voluntarily signed informed consent; * Be able to comply with trial and follow-up procedures; * Adequate bone marrow and organ function; * Patients who have progressed, recurrent or refractory disease after first-line treatment (failure to obtain complete or partial remission after recent treatment); * Fertile women must agree to abstain from sex (abstaining from heterosexual intercourse)or use a highly effective method of contraception for at least one week from the time they sign an informed consent form until the last dose of the study drug. * The blood HCG test must be negative within 7 days before the start of the study treatment, and must be non-lactating; * For male patients whose partner is a woman of reproductive age, they must agree to abstain from sex for at least one week from signing the informed consent until the last dose of the study drug, or to use a highly effective method of contraception. * Immunotherapy: At least 42 days after completing any type of immunotherapy, including immune checkpoint; * Radiation therapy: 60 days should have elapsed in the case of completing radiation. * Cytokine therapy (e.g. G-CSF, GM-CSF, IL-6, IL-2): must be discontinued a minimum of 7 days prior to SL-28 therapy. Exclusion Criteria: * Untreated or active primary central nervous system (CNS) tumor or metastasis; * Patients diagnosed of having primary and secondary immunodeficiencies; * Patients with disease of any major organ system that would compromise their ability to withstand therapy. * Arterial/venous thrombosis events that occurred in the 12 months before enrollment, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; * Known allergy to any of the agents or their ingredients used in this study; * Patients who are on hemodialysis; * Pregnant or breast-feeding women; fertility patients who are unwilling or unable to take effective contraceptive measures; * Patients with untreated positive blood cultures or progressive infections.